UBS analyst Ashwani Verma reiterated a Buy rating and $645.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE